Association between apolipoprotein B/A1 ratio and coronary plaque vulnerability in patients with atherosclerotic cardiovascular disease: an intravascular optical coherence tomography study

Fuxue Deng, Danni Li, Lei Lei, Qiang Yang, Qing Li, Hongtao Wang, Jie Deng*, Qiangsun Zheng* and Wei Jiang*

Abstract

Background: Apolipoprotein (Apo) A1 and Apo B are strongly associated with the risk of atherosclerotic cardiovascular disease (ASCVD). However, the relationship between the Apo B/A1 ratio and the morphology of coronary vulnerable plaques has not been fully elucidated in patients with ASCVD.

Methods: A total of 320 patients with ASCVD undergoing percutaneous coronary intervention were enrolled and assigned into acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) group. The morphology of culprit plaque was analyzed by intravascular optical coherence tomography. Association between the Apo B/A1 ratio and coronary vulnerable plaques were evaluated using logistic regression models and receiver operator characteristic (ROC) curve analyses.

Results: The Apo B/A1 ratio was higher in ACS patients than CCS patients (0.77 ± 0.28 vs. 0.64 ± 0.22, P < 0.001) and it was also higher in patients with plaque rupture, erosion or thrombus than those without culprit plaques. The high Apo B/A1 ratio was associated with high percent of vulnerable plaques compared with low ratio group. The Apo B/A1 ratio was negatively related to fibrous cap thickness in lipid-rich plaque (r = −0.228, P = 0.043). Univariate and multivariate logistic regression analyses revealed that the Apo B/A1 ratio was an independent factor of plaque rupture, erosion, and thrombus. The area under the ROC curve of the Apo B/A1 ratio for plaque rupture, erosion, and thrombus were 0.632, 0.624, and 0.670 respectively (P < 0.001 for all), which were higher than that of low-density lipoprotein cholesterol.

Conclusions: The Apo B/A1 ratio is an independent predictor for plaque rupture, erosion, and thrombus in patients with ASCVD.

Keywords: Optical coherence tomography, Atherosclerotic cardiovascular disease, Apolipoprotein

Background

Apolipoprotein (Apo) A1, a main structural protein of high-density lipoprotein cholesterol (HDL-C), plays a key role in reversing cholesterol flow and cellular cholesterol homeostasis [1]. While Apo B exists as a single protein...
molecule and serves as an alternative factor to low-density lipoprotein cholesterol (LDL-C) for cardiovascular risk assessment [2]. Recent clinical studies indicate that the Apo B/A1 ratio, which may reflect the cholesterol balance between atherogenic and antiatherogenic lipoprotein particles, is a strong predictor of risk for atherosclerotic cardiovascular disease (ASCVD) [3, 4].

According to the latest guidelines, the dynamic nature of the ASCVD process can be categorized as either acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) [5]. Intra-coronary imaging techniques, including intravascular ultrasound (IVUS), optical coherence tomography (OCT), and fractional flow reserve (FFR), are recommended for percutaneous coronary intervention (PCI) in clinical practice [6]. OCT is a high-resolution intravascular imaging modality that can identify the characteristics of different coronary artery plaques [7]. However, the relationship between Apo B/A1 ratio and the morphology of coronary vulnerable plaques has not been fully elucidated in patients with ASCVD. Therefore, this study aims to investigate the association between them in these settings and to determine whether the Apo B/A1 ratio can serve as a predictor of coronary vulnerable plaques.

Methods

Patient population
Patients with ASCVD from the Second Affiliated Hospital of Xi’an Jiaotong University were retrospectively enrolled from August 2019 to December 2020. Data on anthropometry, lifestyle, and medical history were obtained at baseline. Patients (aged ≥18) diagnosed with ASCVD and undergoing PCI were screened for OCT examination. The main exclusion criteria were: cardiogenic shock, end-stage renal disease, serious liver dysfunction, allergy to contrast media, and contraindication to aspirin or ticagrelor. Moreover, patients with left main coronary artery disease, chronic total occlusion, extremely tortuous artery, or heavily calcified vessels were excluded because of potential difficulty in performing OCT examination. Left ventricular ejection fraction (LVEF) was evaluated by echocardiography using modified Simpson’s method within 24 h upon admission.

According to ASCVD guidelines, ACS includes ST-segment elevation myocardial infarction (STEMI), non-ST-segment elevation myocardial infarction (NSTEMI), and unstable angina (UA). CCS are those different evolutionary phases of ASCVD, such as stable angina, asymptomatic and symptomatic patients >1 year after initial diagnosis or revascularization, suspected vasospastic or microvascular disease, but excluding the situations of ACS [5].

Blood collection
Blood samples were taken into tubes containing 0.1% EDTA for serum lipid analyses at the first time when patients were hospitalized. The concentrations of Apo and other relevant lipoprotein markers, such as LDL-C, HDL-C, total cholesterol (TC), and total triglycerides (TG), were measured by electro-chemiluminescence immunoassay (Roche Diagnostics, Indianapolis, IN). Other laboratory parameters were measured according to standard test protocols.

Angiographic procedure
Coronary angiography was performed via the transradial or transfemoral approach with a 6F or 7F sheath. Intravascular infusion of 70–100 IU/kg unfractionated heparin was given prior to PCI. The culprit vessel was determined by coronary angiography results and electrocardiogram or echocardiographic information with proof of possible myocardial ischemia.

OCT imaging and analysis
A commercially available frequency-domain OCT system (OCT Mobile Dragonfly, St. Jude Medical/Abbott, St. Paul, MN, USA) was used in the study. After intracoronary administration of 0.2 mg nitroglycerin, an OCT imaging catheter was advanced distal to the lesion and automated pullback was initiated at a rate of 20 mm/s after flushing with contrast media manually from the guiding catheter to create a virtually blood-free environment. The total length of OCT pullback was 75 mm. Thrombus aspiration and/or gentle predilation with small balloon were applied for acute total occluded lesions or severe stenosis lesions as per need to make sure that the OCT catheter could pass through smoothly.

Definitions of image characteristics on OCT were based mainly on previous consensus [7]. Culprit plaques were classified as fibrous plaque with homogeneous and highly backscattering regions (Fig. 2a) or lipid-rich plaque with low signal regions and diffuse borders (Fig. 2b). The fibrous cap thickness (FCT) of a fibrous plaque or lipid-rich plaque was measured three times and the average value was calculated. The lipid arc was measured at 1-mm intervals throughout the entire lesion, and the largest arc was recorded. Calcification within plaques was identified by the presence of sharply delineated, low-backscattering heterogeneous regions (Fig. 2c). Calcium arc and depth were measured using cross-sectional OCT images at 1-mm intervals. The length of the calcification lesion was measured as the span of the entire culprit plaque in the longitudinal view. Thin-cap fibroatheroma (TCFA) was defined as a
lipid-rich plaque with the thinnest part of the fibrous cap being less than 65 μm (Fig. 2d).

Plaque rupture was identified by disruption of the fibrous cap with obvious cavity formation (Fig. 1e). Plaque erosion was defined as the presence of attached thrombus overlying an intact and visualized plaque (Fig. 1f). Calcified nodule was recognized as a nodular calcification that protruded to the lumen with thrombus formation (Fig. 2g). Thrombus was defined as irregular mass that adhered to the luminal surface including white thrombus, red thrombus, and mixed thrombus (Fig. 2h).

Macrophages were defined as signal-rich, distinct or confluent punctuate regions with heterogeneous backward shadows (Fig. 2i). Cholesterol crystals were defined as linear, highly backscattering structures within the plaque (Fig. 2j). Microvessels were defined as black holes within a plaque that were presented on at least three consecutive frames (Fig. 2k). In-stent restenosis was defined as stenosis greater than 50% of the vessel lumen diameter after stent was implanted (Fig. 2l). All OCT images were analyzed on an OCT workstation by three independent investigators who were blinded to angiographic and clinical data.

**Statistical analysis**

All analyses were performed using SPSS 26.0 statistical software (SPSS Inc, Chicago, IL, USA). Continuous data are presented as mean ± standard deviation (SD) and were compared using independent samples t-test or Mann–Whitney U test between two groups. Categorical data are presented as number (%), and were compared using the Chi-square or Fisher’s exact test. Correlations between variables were determined using the Pearson test or Spearman’s rank test, as appropriate. Logistic regression analyses with adjustments for confounding factors were used to determine association of Apo B/A1 ratio with vulnerable plaques. The predictive value of the Apo B/A1 ratio for plaque rupture, erosion, and thrombus was further examined by receiver operator characteristic (ROC) curve analysis. A two-tailed P value less than 0.05 was considered statistically significant.

**Results**

**Baseline characteristics**

We enrolled 348 patients who presented with ASCVD and underwent OCT examination from August 2019 to December 2020 in our hospital. Among these patients, 28 patients were excluded because of poor OCT imaging quality (n = 17) and lack of enough laboratory test for vulnerable-plaques. The predictive value of the Apo B/A1 ratio for plaque rupture, erosion, and thrombus was further examined by receiver operator characteristic (ROC) curve analysis. A two-tailed P value less than 0.05 was considered statistically significant.

![Study flow chart of this study.](image)

**Fig. 1** Study flow chart of this study. OCT, optical coherence tomography; hs-cTnI, high-sensitivity cardiac troponin I; ACS acute coronary syndrome, CCS chronic coronary syndrome
Finally, 320 patients were enrolled into this study and classified into the ACS (n = 139) and CCS (n = 181) groups according to clinical diagnosis and their clinical presentation. The study flow chart is displayed in Fig. 1.

Of the 320 enrolled patients, 77.8% were males, and the mean age was 59.7 years. The comparison of baseline clinical characteristics between ACS and CCS groups is listed in Table 1. The angiographic findings of culprit vessels and number of stents implanted into these patients were also presented. No significant differences were observed in terms of age, medical history or alcohol drinking between ACS and CCS groups. However, more males, higher percentage of smoking habits, and longer smoking years were presented in ACS group. The acute phase biomarkers including white blood cells (WBCs) and myocardial injury markers were also higher in ACS group, which were consistent with the pathogenesis of ACS. In terms of serum lipid profile, the concentrations of TC, HDL-C, LDL-C, lipoprotein (a), Apo A1, Apo B, and the Apo B/A1 ratio were significantly higher in ACS group than that in the CCS group (P < 0.05). However, the LVEF was lower in ACS group, indicating the reduced systolic function of the heart in patients with ACS (P < 0.001). No difference was found in the statins taken at admission between the two groups (P = 0.531).

Fig. 2 Representative cross-sectional optical coherence tomography images of culprit vessels. a Fibrous plaque identified as homogeneous and highly backscattering region. b Lipid-rich plaque identified as a low signal region with a diffuse border. c Calcification identified as sharply-delineated, low-backscattering heterogeneous regions. d Thin-cap fibroatheroma (TCFA) identified as a lipid-rich plaque with the thinnest part of the fibrous cap being less than 65 μm (arrow). e Plaque rupture identified as disruption of the fibrous cap with obvious cavity formation (arrow). f Plaque erosion identified as the presence of attached thrombus overlying an intact and visualized plaque. g Calcified nodule identified as a nodular calcification that protruded to the lumen with thrombus formation (arrow). h Thrombus defined as irregular mass that adhered to the luminal surface including white thrombus, red thrombus, and mixed thrombus. i Macrophages defined as signal-rich, distinct or confluent punctuate regions with heterogeneous backward shadows (arrow). j Cholesterol crystals defined as linear, highly backscattering structures within the plaque (arrow). k Microvessels defined as black holes within a plaque that were presented on at least three consecutive frames (arrow). l In-stent restenosis was defined as stenosis greater than 50% of the vessel lumen diameter (arrow)
| Characteristics | All (n = 320) | ACS (n = 139) | CCS (n = 181) | P value |
|-----------------|--------------|--------------|--------------|---------|
| Male, n (%)     | 249 (77.8%)  | 121 (87.1%)  | 128 (70.7%)  | <0.001  |
| Age, years, mean ± SD | 59.70 ± 10.45 | 58.99 ± 11.88 | 60.25 ± 9.21 | 0.283   |
| Medical history, n (%) |              |              |              |         |
| Atrial fibrillation | 11 (3.4%)    | 10 (7.2%)    | 1 (0.6%)     | 0.001   |
| Hypertension     | 166 (51.9%)  | 79 (56.8%)   | 87 (48.1%)   | 0.120   |
| Diabetes mellitus | 80 (25.0%)   | 32 (23.0%)   | 48 (26.5%)   | 0.474   |
| ASCVD            | 148 (46.3%)  | 60 (43.2%)   | 88 (48.6%)   | 0.332   |
| Prior PCI        | 65 (20.3%)   | 30 (21.6%)   | 35 (19.3%)   | 0.621   |
| Stroke           | 19 (5.9%)    | 10 (7.2%)    | 9 (5.0%)     | 0.404   |
| Alcohol drinking | 50 (15.6%)   | 28 (20.1%)   | 22 (12.2%)   | 0.051   |
| Smoking          | 141 (44.1%)  | 71 (51.1%)   | 70 (38.7%)   | 0.027   |
| Smoking years    | 12.90 ± 15.94| 15.14 ± 16.36| 11.71 ± 15.43| 0.027   |
| Laboratory results, mean ± SD |            |              |              |         |
| WBC, x 10^9/L   | 7.00 ± 2.36  | 7.89 ± 2.84  | 6.32 ± 1.63  | <0.001  |
| Hb, g/L         | 140.76 ± 17.51| 138.63 ± 19.88 | 142.39 ± 15.30 | 0.057   |
| HbA1c, %        | 6.48 ± 1.70  | 6.43 ± 1.76  | 6.52 ± 1.65  | 0.671   |
| NT-proBNP, pg/ml | 670.25 ± 1906.92| 1345.28 ± 2727.79| 147.76 ± 296.54 | <0.001  |
| Hs-cTnI, pg/ml  | 292.11 ± 978.31| 631.49 ± 1376.67| 7.93 ± 2.82  | <0.001  |
| Glucose, mmol/L | 6.15 ± 2.40  | 6.39 ± 2.91  | 5.98 ± 1.99  | 0.266   |
| Creatine, μmol/L| 77.10 ± 80.41| 91.36 ± 119.68| 66.15 ± 14.16| 0.005   |
| eGFR, ml/min/1.73m² | 104.43 ± 28.09 | 102.07 ± 33.01 | 106.24 ± 23.57 | 0.188   |
| Uric acid, μmol/L| 312.55 ± 80.69| 332.93 ± 83.66 | 297.46 ± 75.18 | <0.001  |
| TC, mmol/L       | 3.79 ± 0.99  | 3.95 ± 1.01  | 3.68 ± 0.95  | 0.016   |
| TG, mmol/L       | 1.71 ± 1.35  | 1.85 ± 1.55  | 1.61 ± 1.17  | 0.116   |
| HDL-C, mmol/L    | 1.06 ± 0.26  | 1.02 ± 0.24  | 1.08 ± 0.26  | 0.023   |
| LDL-C, mmol/L    | 2.23 ± 0.84  | 2.42 ± 0.87  | 2.09 ± 0.80  | <0.001  |
| VLDL-C, mmol/L   | 0.52 ± 0.47  | 0.53 ± 0.51  | 0.51 ± 0.45  | 0.663   |
| Apo A1, g/L      | 1.25 ± 0.26  | 1.20 ± 0.23  | 1.29 ± 0.27  | 0.001   |
| Apo B, g/L       | 0.84 ± 0.25  | 0.89 ± 0.27  | 0.81 ± 0.23  | 0.003   |
| Apo B/A1         | 0.70 ± 0.25  | 0.77 ± 0.28  | 0.64 ± 0.22  | <0.001  |
| Lipoprotein (a), mg/dl | 23.24 ± 28.42 | 25.05 ± 28.99 | 21.84 ± 27.98 | 0.319   |
| TSH, μIU/ml      | 3.51 ± 5.12  | 3.25 ± 5.09  | 3.71 ± 5.15  | 0.439   |
| D-dimer, μg/ml   | 564.49 ± 1354.78| 749.41 ± 1765.73| 422.49 ± 903.22 | 0.032   |
| LVEF, %          | 62.82 ± 7.81  | 60.77 ± 7.76  | 64.50 ± 7.46  | <0.001  |
| Culprit vessels, n (%) |          |              |              |         |
| LAD              | 191 (59.7%)  | 70 (50.4%)   | 121 (66.9%)  | 0.016   |
| LCX              | 40 (12.5%)   | 20 (14.4%)   | 20 (11.0%)   |         |
| RCA              | 56 (17.5%)   | 32 (23.0%)   | 24 (13.3%)   |         |
| Lesion site, n (%)|              |              |              |         |
| Proximal         | 165 (51.6%)  | 72 (51.8%)   | 93 (51.4%)   |         |
| Middle           | 109 (34.1%)  | 41 (29.5%)   | 68 (37.6%)   |         |
| Distal           | 13 (4.1%)    | 9 (6.5%)     | 4 (2.2%)     |         |
| Stents, n (%)    |              |              |              |         |
| 0                | 95 (29.7%)   | 28 (20.1%)   | 67 (37.0%)   |         |
| 1                | 124 (38.8%)  | 55 (39.6%)   | 69 (38.1%)   |         |
| 2                | 67 (20.9%)   | 30 (21.6%)   | 37 (20.4%)   |         |
| 3                | 21 (6.6%)    | 16 (11.5%)   | 5 (2.8%)     |         |
| > 3              | 13 (4.1%)    | 10 (7.2%)    | 3 (1.7%)     |         |
| Statins, n (%)   | 208 (65.0%)  | 93 (66.9%)   | 115 (63.5%)  | 0.531   |
OCT findings of culprit plaques

The detailed comparisons of OCT findings between ACS and CCS patients are listed in Table 2. The percentage of plaque rupture was higher than erosion and calcified nodules both in ACS and CCS groups, while the percentage of vulnerable plaques, including rupture, erosion, and thrombus, was higher in ACS group than that in the CCS group (P < 0.001) except for calcified nodule. No significant difference was observed between them in other common plaque types, such as fibrous plaque, lipid-rich plaque, and calcification plaques. Furthermore, the ratio of Apo B/A1 was higher in plaque rupture, erosion, and thrombus groups than that in non-vulnerable plaque groups (P < 0.001 or P < 0.05) (Table 3). Furthermore, we divided subjects into two groups according to the median value of the Apo B/A-1 ratio: low ratio (< 0.67, n = 160, 50.0%) and high ratio (≥ 0.67, n = 160, 50.0%). Detailed baseline characteristics, such as clinical, laboratorial and OCT morphological information were compared between two groups (Table 4).

Table 2  Optical coherence tomography characteristics of patients in ACS and CCS groups

| Characteristics                     | All (n = 320) | ACS (n = 139) | CCS (n = 181) | P value |
|-------------------------------------|--------------|--------------|--------------|---------|
| Plaque morphology, n (%)           |              |              |              |         |
| Plaque rupture                      | 79 (24.7%)   | 50 (36.0%)   | 29 (16.0%)   | <0.001  |
| Plaque erosion                      | 43 (13.4%)   | 31 (22.3%)   | 12 (6.6%)    | <0.001  |
| Calcified nodule                    | 12 (3.8%)    | 6 (4.3%)     | 6 (3.3%)     | 0.640   |
| Plaque type, n (%)                  |              |              |              |         |
| Thrombus                            | 89 (27.8%)   | 60 (43.2%)   | 29 (16.0%)   | <0.001  |
| Red thrombus                        | 7 (2.2%)     | 4 (2.9%)     | 3 (1.7%)     |         |
| White thrombus                      | 53 (16.6%)   | 34 (24.5%)   | 19 (10.5%)   |         |
| Mixed thrombus                      | 29 (9.1%)    | 22 (15.8%)   | 7 (3.9%)     |         |
| TCFA                                | 16 (5.0%)    | 7 (5.0%)     | 9 (5.0%)     | 0.979   |
| Fibrous plaque                      | 137 (42.8%)  | 58 (41.7%)   | 79 (43.6%)   | 0.731   |
| FCT of fibrous plaque, μm           | 960.99 ± 323.80 | 954.34 ± 300.78 | 965.57 ± 340.60 | 0.847   |
| Calcification                        | 86 (26.9%)   | 33 (23.7%)   | 53 (29.3%)   | 0.268   |
| Angle, °                            | 183.46 ± 115.16 | 198.42 ± 112.44 | 173.79 ± 117.04 | 0.357   |
| Thickness, mm                       | 0.84 ± 0.29  | 0.79 ± 0.33  | 0.88 ± 0.26  | 0.218   |
| Length, mm                          | 22.99 ± 12.10 | 22.83 ± 10.06 | 23.09 ± 13.36 | 0.931   |
| Lipid-rich plaque                    | 79 (24.7%)   | 28 (20.1%)   | 51 (28.2%)   | 0.099   |
| FCT, μm                             | 147.39 ± 125.66 | 145.97 ± 141.54 | 148.24 ± 116.62 | 0.938   |
| Lipid arc, °                        | 188.86 ± 66.37 | 202.62 ± 59.50 | 180.88 ± 69.36 | 0.162   |
| Cholesterol crystal                 | 137 (42.8%)  | 63 (45.3%)   | 74 (40.9%)   | 0.426   |
| Micro-vessel                        | 63 (21.6%)   | 24 (17.3%)   | 45 (24.9%)   | 0.101   |
| Macrophage                          | 61 (19.1%)   | 27 (19.4%)   | 34 (18.8%)   | 0.885   |
| In-stent restenosis, n (%)          | 43 (13.4%)   | 21 (15.1%)   | 22 (12.2%)   | 0.443   |
| Quantitative of target vessel       |              |              |              |         |
| MLA, mm²                            | 2.24 ± 1.52  | 2.16 ± 1.61  | 2.30 ± 1.45  | 0.440   |
| MLD, mm                             | 1.61 ± 0.48  | 1.56 ± 0.51  | 1.64 ± 0.46  | 0.218   |
| Diameter stenosis, %                | 43.16 ± 12.99 | 44.91 ± 13.04 | 41.86 ± 12.84 | 0.050   |
| Area stenosis, %                    | 66.56 ± 16.31 | 68.59 ± 15.92 | 65.04 ± 16.49 | 0.070   |
| Reference vessel diameter, mm       | 2.53 ± 0.66  | 2.48 ± 0.72  | 2.56 ± 0.61  | 0.335   |
| Post-stent MLA, mm²                  | 4.87 ± 2.01  | 4.89 ± 1.75  | 4.85 ± 2.23  | 0.914   |

ACS acute coronary syndrome, CCS chronic coronary syndrome, TCFA thin-cap fibroatheroma, FCT fibrous cap thickness, MLA minimal lumen area, MLD minimal lumen diameter
Patients with high Apo B/A1 ratio were younger males with fewer diabetes mellitus (DM). The high ratio group was associated with high percent of plaque rupture, erosion, and thrombus, but not calcified nodule. No difference was found in the statins taken between the two groups ($P = 0.160$).

The correlation study showed that the Apo B/A1 ratio was negatively related to the FCT in lipid-rich plaque ($r = -0.228$, $P = 0.043$) (Fig. 3). Univariate logistic regression analysis revealed that the Apo B/A1 ratio was closely associated with plaque rupture (Table 5), erosion (Additional file 1: Table S1), and thrombus (Additional file 2: Table S2). After adjusting for confounding factors, such as age, sex, medical history, alcohol drinking, and smoking in different models for multivariate logistic regression analysis, the Apo B/A1 ratio remained predictive for plaque rupture, erosion, and thrombus ($P < 0.05$).

The predictive value of the Apo B/A1 ratio and LDL-C for vulnerable plaques was further examined by ROC curve analysis. In plaque rupture group, the area under the curve (AUC) were 0.632 (95% CI 0.562–0.702, $P < 0.001$) for Apo B/A1 and 0.614 (95% CI 0.544–0.683, $P = 0.003$) for LDL-C (Fig. 4). In plaque erosion group, AUC were 0.624 (95% CI 0.538–0.710, $P < 0.001$) for Apo B/A1 and 0.605 (95% CI 0.520–0.691, $P = 0.027$) for LDL-C (Additional file 3: Fig. S1). In thrombus group, AUC were 0.648 (95% CI 0.579–0.716, $P < 0.001$) for Apo B/A1 and 0.614 (95% CI 0.545–0.682, $P = 0.002$) for LDL-C (Additional file 4: Fig. S2).

**Discussion**

In the present study, the association between the Apo B/A1 ratio and OCT characteristics of coronary vulnerable plaques in patients with ASCVD were investigated. We found that the Apo B/A1 ratio was higher in patients with plaque rupture, erosion, thrombus, and calcification but not calcified nodules, indicating that Apo B/A1 may be associated with coronary vulnerable plaques. The high Apo B/A1 ratio group was associated with high percent of plaque rupture, erosion, and thrombus. Moreover, we revealed that the Apo B/A1 ratio is an independent factor of culprit vulnerable plaques in the method of logistic regression analyses. Apo B/A1 ratio also demonstrates better predictive value of coronary vulnerable plaques compared with LDL-C.

**Apolipoprotein and ASCVD**

In recent years, Apos have been found to be strongly associated with the risk of STEMI, and Apo B/A1 ratio is a better risk biomarker of acute myocardial infarction than LDL-C or TC/HDL-C ratio [8, 9]. A low LDL-C/Apo B ratio was found to be associated with neointimal proliferation and neointimal instability after everolimus-eluting stent implantations [10]. A cross-sectional study found that combined evaluation of triglyceride-rich lipoprotein-related markers and the LDL-C/Apo B ratio may be of increasing importance in the risk stratification of ASCVD patients with DM [11].

The Apo B/A1 ratio is a useful tool of risk assessment in patients presenting with NSTEMI including prediction of coronary multi-vessel affection [12]. It is also an independent predictor for complicated lesions and future myocardial infarction in patients with DM and ACS [3].
Table 4  Baseline characteristic of patients in the low and high Apo B/A1 ratio groups

| Characteristics                      | Low ratio (n = 160) | High ratio (n = 160) | P value |
|--------------------------------------|--------------------|----------------------|---------|
| Male, n (%)                          | 110 (68.8%)        | 139 (86.9%)          | <0.001  |
| Age, years, mean ± SD                | 61.87 ± 10.10      | 57.54 ± 10.38        | <0.001  |
| Medical history, n (%)               |                    |                      |         |
| Atrial fibrillation                  | 7 (4.4%)           | 4 (2.5%)             | 0.357   |
| Hypertension                         | 91 (56.9%)         | 75 (46.9%)           | 0.073   |
| Diabetes mellitus                    | 51 (31.9%)         | 29 (18.1%)           | 0.005   |
| ASCVD                                | 78 (48.8%)         | 70 (43.8%)           | 0.370   |
| Prior PCI                            | 33 (20.6%)         | 32 (20.0%)           | 0.889   |
| Stroke                               | 10 (6.3%)          | 9 (5.6%)             | 0.813   |
| Laboratory results, mean ± SD       |                    |                      |         |
| HbA1c, %                             | 6.42 ± 1.59        | 6.54 ± 1.80          | 0.530   |
| NT-proBNP, pg/ml                     | 607.48 ± 1671.90   | 734.63 ± 2124.78     | 0.556   |
| Hs-cTnI, pg/ml                       | 249.97 ± 1060.65   | 333.98 ± 890.54      | 0.454   |
| TC, mmol/L                           | 3.28 ± 0.76        | 4.30 ± 0.92          | <0.001  |
| TG, mmol/L                           | 1.37 ± 0.68        | 2.04 ± 1.71          | <0.001  |
| HDL-C, mmol/L                        | 1.15 ± 0.27        | 0.96 ± 0.20          | <0.001  |
| LDL-C, mmol/L                        | 1.72 ± 0.62        | 2.73 ± 0.72          | <0.001  |
| VLDL-C, mmol/L                       | 0.42 ± 0.26        | 0.62 ± 0.60          | <0.001  |
| Lipoprotein (a), mg/dl               | 19.56 ± 24.56      | 26.85 ± 31.42        | 0.022   |
| LVEF, %                              | 63.12 ± 7.17       | 62.52 ± 8.40         | 0.529   |
| Plaque morphology, n (%)             |                    |                      |         |
| Plaque rupture                       | 27 (16.9%)         | 52 (32.5%)           | 0.001   |
| Plaque erosion                       | 12 (7.5%)          | 31 (19.4%)           | 0.002   |
| Calcified nodule                     | 7 (4.4%)           | 5 (3.1%)             | 0.556   |
| Thrombus                             | 30 (18.8%)         | 59 (36.9%)           | <0.001  |
| TCFA                                 | 6 (3.8%)           | 10 (6.3%)            | 0.305   |
| Fibrous plaque                       | 64 (40.0%)         | 73 (45.6%)           | 0.309   |
| FCT, μm                              | 955.02 ± 347.42    | 966.28 ± 303.87      | 0.844   |
| Calcification                        | 56 (35.0%)         | 30 (18.8%)           | 0.001   |
| Angle, °                             | 171.09 ± 122.51    | 208.65 ± 95.80       | 0.142   |
| Thickness, mm                        | 0.82 ± 0.27        | 0.89 ± 0.33          | 0.310   |
| Length, mm                           | 22.30 ± 11.18      | 24.48 ± 14.02        | 0.489   |
| Lipid-rich plaque                    | 39 (24.4%)         | 40 (25.0%)           | 0.897   |
| FCT, μm                              | 181.46 ± 154.11    | 114.98 ± 80.11       | 0.020   |
| Lipid arc, °                         | 191.38 ± 72.15     | 186.40 ± 61.03       | 0.741   |
| Cholesterol crystal                  | 64 (40.0%)         | 73 (45.6%)           | 0.309   |
| Micro-vessel                         | 32 (20.0%)         | 37 (23.1%)           | 0.497   |
| Macrophage                           | 34 (21.3%)         | 27 (16.9%)           | 0.319   |
| Stents, n (%)                        |                     |                      |         |
| 0                                    | 56 (35.0%)         | 39 (24.4%)           |         |
| 1                                    | 57 (35.6%)         | 67 (41.9%)           |         |
| 2                                    | 29 (18.1%)         | 38 (23.8%)           |         |
| 3                                    | 11 (6.9%)          | 10 (6.3%)            |         |
| > 3                                  | 7 (4.4%)           | 6 (3.8%)             |         |
| Statins, n (%)                       | 98 (61.3%)         | 110 (68.8%)          | 0.160   |

ASCVD atherosclerotic cardiovascular disease, PCI percutaneous coronary intervention, SD standard deviation, HbA1c glycosylated hemoglobin, NT-proBNP N-terminal B-type natriuretic peptide, Hs-cTnI high-sensitivity cardiac troponin I, TC total cholesterol, TG total triglycerides, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol, Apo apolipoprotein, LVEF left ventricular ejection fraction, TCFA thin-cap fibroatheroma, FCT fibrous cap thickness
In the present study, we also found that Apo A1, Apo B, and Apo B/A1 ratio showed a significant difference between ACS and CCS groups, which was consistent with previous study.

OCT findings and ASCVD
Atherosclerotic plaque components such as TCFA, macrophage infiltration, large necrotic core, and thrombus in patients with ASCVD can be detected with high-resolution imaging modalities including IVUS and OCT [13]. Given its extremely high resolution (<10 μm) similar to histological biopsy, OCT is usually considered as a technique of in vivo optical biopsy. OCT can distinguish plaque rupture, erosion, and other plaque phenotypes by its optical sensor, which improves disease diagnosis and optimizes therapy. Previous studies have found that plaque rupture, erosion, and calcified nodules are the three main causes of ACS [14, 15]. Plaque rupture is responsible for nearly half of patients with ACS, while plaque erosion and calcified nodes account for 1/3 of patients and 2–7% of acute coronary events, respectively [16, 17]. Other causes of ACS include spontaneous dissection, tight stenosis, and intramural hematoma [18].

Plaque rupture is often associated with large lipid-rich plaque burden and red thrombus, while white thrombus is usually found in plaque erosion [19]. A large study found that approximately 2/3 of plaque erosion cases presented as NSTEMI [20]. However, a meta-analysis revealed that plaque rupture is responsible for 70% of STEMI, 56% of NSTEMI, 39% of unstable angina, and 6% patients of stable angina [21]. In addition, high prevalence of plaque rupture was observed in long duration of

**Table 5** Logistic regression analysis of plaque rupture

| Variables        | OR    | 95% CI          | P value |
|------------------|-------|-----------------|---------|
| Apo B/A1         | 5.499 | 2.019–14.972    | 0.001   |
| Apo B            | 4.776 | 1.716–13.288    | 0.003   |
| Apo A1           | 0.470 | 0.163–1.359     | 0.163   |
| TG               | 1.151 | 0.968–1.368     | 0.110   |
| TC               | 1.412 | 1.094–1.821     | 0.008   |
| HDL-C            | 0.473 | 0.167–1.345     | 0.160   |
| LDL-C            | 1.537 | 1.137–2.078     | 0.005   |
| VLDL-C           | 1.524 | 0.921–2.523     | 0.101   |
| Lipoprotein (a)  | 1.008 | 1.000–1.016     | 0.064   |
| Model 1          | 6.257 | 2.232–17.541    | <0.001  |
| Model 2          | 4.547 | 1.583–13.067    | 0.005   |
| Model 3          | 4.927 | 1.676–14.481    | 0.004   |

Model 1: Apo B/A1, AF, HBP and DM
Model 2: Apo B/A1, AF, HBP, DM, age and sex
Model 3: Apo B/A1, AF, HBP, DM, age, sex, alcohol drinking and smoking

Apo apolipoprotein, TG total triglycerides, TC total cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, VLDL-C very low-density lipoprotein cholesterol, OR odds ratio, CI confidence interval
DM and high glycosylated hemoglobin (HbA1c) in DM patients with STEMI [22].

In this study, the percentage of plaque rupture was higher than plaque erosion and calcified nodule in patients with ASCVD, while the Apo B/A1 ratio in plaque rupture or erosion groups were both higher in ACS than that of CCS patients (rupture: 36.0 vs. 16.0% and erosion: 22.3 vs. 6.6%). For thrombus, white thrombus was more commonly detected than red thrombus (16.6 vs. 2.2%). The possible reason may be that the percentage of OCT usage in STEMI patients with totally occluded vessel featured with red thrombus was less than that in NSTEMI patients in our study.

To some extent, plaque erosion may overlap with plaque rupture in the setting of TCFA or thick-cap fibroatheroma, which means that plaque erosion with underlying TCFA might harbor small ruptures [23]. Cholesterol crystals, a hallmark of advanced atherosclerotic lesions, were found to be associated with characteristics of vulnerable plaques in ACS culprit lesions [24, 25]. Abundant and homogeneous macrophage accumulation in coronary arterial wall was also found in ACS patients with DM [26]. Another study investigated non-culprit plaque in STEMI patients, and found that STEMI patients with culprit plaque erosion have a limited pan-coronary vulnerability than STEMI patients with plaque rupture, which may also explain the better outcomes in patients with erosion than rupture [27]. Patients with plaque erosion had fewer other coronary risk factors (dyslipidemia, hypertension, chronic kidney disease, and DM) than those with plaque rupture [28]. On the basis of the difference of the pathogenesis of plaque rupture and erosion, ACS patients with plaque rupture should be treated with stent implantation, while those with plaque erosion should be treated with antithrombotic and anti-platelet therapy. Our study also revealed that more stents were implanted in ACS patients with plaque rupture than that in CCS group.

**Biomarkers and vulnerable plaques**

Although OCT has many advantages, it is ultimately an invasive procedure with low accessibility, high cost, and possible complication risks. Thus, biomarkers that can identify vulnerable plaques in patients with ACS need to be developed. Some serum biomarkers have already been identified to be related to plaque rupture or erosion [29]. High HbA1c and random plasma glucose on admission were found to be positively correlated with vulnerable plaques.

![Fig. 4](image.png) Receiver operating characteristic (ROC) curve for differentiating rupture group from non-rupture group. AUC = area under the curve, LDL-C = low-density lipoprotein cholesterol
plaque in STEMI patients [30]. Matrix metalloproteinase-9 (MMP-9), also known as gelatinase B or 92 kDa type IV collagenase, is expressed in atherosclerotic plaques and associated with the vulnerability of plaques including TCFA [31, 32]. MMP-9 can serve as a marker for plaque rupture and predictor of poor clinical outcomes in ACS patients [33]. Low adiponectin level has been shown to be a risk factor for adverse cardiovascular events as adiponectin is involved in the pathogenesis of vulnerability to coronary lesions [34, 35]. Moreover, a significant correlation was observed between low adiponectin levels and plaque rupture, TCFA, and lipid-rich plaque [36]. Serum 1,5-anhydroglucitol also identified high risk for coronary plaque rupture in diabetic patients with ACS [37]. Plasma pentraxin-3 level was associated with plaque vulnerability in patients with ASCVD [38, 39]. Another study indicated that a low ratio of eicosapentaenoic acid to arachidonic acid was associated with higher vulnerability of coronary plaques to rupture [40]. The triglyceride glucose index combined with the morphological characteristics of plaque could be used to predict adverse events in patients with STEMI [41]. The combination of different biomarkers, such as soluble lectin-like oxidized LDL receptor-1, MMP-9, WBC count, and peak creatine kinase-MB, could also be used to identify plaque rupture compared with other individual biomarkers in patients with ACS [18].

It has been proved that a high level of LDL-C is a key risk factor for ASCVD [42]. Many clinical guidelines have shown that statins lower the incidence of ASCVD by reducing the levels of LDL-C, lipid content of plaques, and FCT [43, 44]. Patients with low level of LDL-C who were treated with statins had a higher prevalence of calcification, which means that statins may help to prevent plaque rupture by calcification [45]. However, the addition of proprotein convertase subtilisin/kexin type 9 inhibitor to statin therapy might produce incremental growth in FCT and regression of the lipid-rich plaque after onset of ACS, thus decreasing the incidence of plaque rupture [46].

In terms of lipoprotein and vulnerable plaque phenotype, the reduction of LDL-C and high-sensitivity C-reactive protein was related to changes in total atheroma volume and FCT of residual non-culprit lipid-rich plaques [47]. ACS patients with residual cholesterol risk were found to be associated with atherosclerotic plaque and plaque rupture, indicating that residual cholesterol risk was an independent risk factor of plaque rupture [48]. The levels of lipoprotein (a), an independent risk factor for ASCVD, are associated with an increased atherosclerotic burden, such as higher prevalence of lipidic plaque, wider lipid arc, and higher prevalence of TCFA [49]. Lowering lipoprotein (a) levels by alirocumab contributed independently to cardiovascular event reduction [50]. We found that the Apo B/A1 ratio has a negative correlation with FCT in lipid-rich plaque, indicating the higher Apo B/A1 ratio, the less stable status of TCFA in lipid-rich plaques. Lowering the Apo B/A1 ratio may decrease the incidence of presentation of TCFA and ACS, which need more work to be done in the future. In this study, the ROC curve of Apo B/A1 and LDL-C indicated good sensitivity and specificity for coronary vulnerable plaques. However, the AUC of ROC curve of Apo B/A1 is larger than LDL-C. On the basis of these results, the Apo B/A1 ratio may serve as a better biomarker for vulnerable plaques in patients with ASCVD compared with LDL-C.

Study limitations
This study has several limitations. First, this study was a retrospective and observational study conducted in one center with a small sample size. Second, we did not classify STEMI, NSTEMI, and UA in the study. Third, most samples were obtained at the time of hospitalization before OCT examination, but a number of blood samples were obtained after that, especially in STEMI and critical patients with high-risk. Fourth, the decision to perform OCT was up to different operators, and potential selection bias may not be excluded. Fifth, calcified nodules were rare in our study. More patients should be enrolled in the future studies.

Conclusions
We found that the Apo B/A1 ratio was higher in ACS patients than that of CCS patients, and it was associated with coronary culprit plaques, including plaque rupture, erosion, and thrombus. The Apo B/A1 ratio is an independent predictor for coronary vulnerable plaques in patients with ASCVD.

Abbreviations
Apo: Apolipoprotein; ASCVD: Atherosclerotic cardiovascular disease; ACS: Acute coronary syndrome; CCS: Chronic coronary syndrome; DM: Diabetes mellitus; OCT: Optical coherence tomography; LDL-C: Low-density lipoprotein cholesterol; HDL-C: High-density lipoprotein cholesterol; PCI: Percutaneous coronary intervention; hs-cTnI: High-sensitivity cardiac troponin I; FCT: Fibrous cap thickness; TCFA: Thin-cap fibroatheroma; STEMI: ST-segment elevation myocardial infarction; NSTEMI: Non-ST-segment elevation myocardial infarction; UA: Unstable angina; WBC: White blood cells; TC: Total cholesterol; TG: Total triglycerides; ROC: Receiver operator characteristic; AUC: Area under the curve; MPP-9: Matrix metalloproteinase-9.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12933-021-01381-9.

Additional file 1: Table S1 Logistic regression analysis of plaque erosion.
Acknowledgements
The authors thank the study subjects for their participation and support of this study.

Authors’ contributions
WJ contributed to the study design, data acquisition, and data analysis and wrote the manuscript. FD and HW contributed to the study design. FD, DL, QY, KL, and LL contributed to the data acquisition. JD, QZ, and WJ reviewed and edited the intellectual content. All authors gave final approval for this version to be published. All authors read and approved the final manuscript.

Funding
This work was supported by the Natural Science Foundation of Shaanxi Province (2021JM-291).

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Xi’an Jiaotong University, and the study was conducted according to the principles of the Helsinki Declaration II. All patients provided written informed consent.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Received: 15 July 2021 Accepted: 7 September 2021
Published online: 15 September 2021

References

1. Yaseen RI, El-Leboudy MH, El-Deeb HM. The relation between ApoB/ ApoA-1 ratio and the severity of coronary artery disease in patients with acute coronary syndrome. Egypt Heart J 2021;73(1):24.
2. Sierra-Johnson J, Fisher RM, Romero-Corral A, Somers VK, Lopez-Jimenez F, Ohrvik J, Walldius G, Hellenius ML, Hamsten A. Concentration of apolipoprotein B is comparable with the apolipoprotein B/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multi-ethnic US population. Eur Heart J 2009;30(6):710–7.
3. Liu Y, Jia SD, Yuan DS, Xu N, Jiang L, Gao Z, Chen J, Yang YJ, Gao RL, Xu B, et al. Apolipoprotein B/A-I ratio predicts lesion severity and clinical outcomes in diabetic patients with acute coronary syndrome. Circ J. 2020;84(7):1132–9.
4. Holme I, Aastveit AH, Jungner I, Walldius G. Relationships between lipoprotein components and risk of myocardial infarction: age, gender and short versus longer follow-up periods in the Apolipoprotein MOrtality RIsk study (AMORIS). Int Med. 2008;264(1):30–41.
5. Knuts J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–77.
6. Raber L, Mintz GS, Koskinas KC, Johnson TW, Holm NR, Onuma Y, Radu MD, Joner M, Yu B, Jia H, et al. Clinical use of intracoronary imaging. Part 1: guidance and optimization of coronary interventions. An expert consensus document of the European Association of Percutaneous Cardiovascular Interventions. Eurointervention. 2018;14(6):656–77.
7. Teamey GJ, Regar E, Akasaka T, Adriaenssens T, Barlis P, Bezzerra HG, Bouma B, Bruining N, Cho JW, Chowdry S, et al. Consensus standards for acquisition, measurement, and reporting of intravascular optical coherence tomography studies: a report from the International Working Group on Intravascular Optical Coherence Tomography Standardization and Validation. J Am Coll Cardiol. 2012;59(12):1058–72.
8. McQueen MJ, Hawken S, Wang X, Ounpuu S, Simesder A, Probstfield J, Steyn K, Sanderson JE, Hasani M, Volokova E, et al. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. Lancet. 2008;372(9634):224–33.
9. Bodde MC, Hermans MPJ, Jukema JW, Slalji MW, Rosendaal FR, Romijn F, Ruhaak LR, van der Laarse A, Cobbaert CM. Apolipoproteins A1, A, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol. 2019;108(5):520–38.
10. Akatsu N, Hon K, Mizebuchi S, Ogiaku A, Koyama Y, Fujito H, Arai R, Ebuchi Y, Mijita S, Morikawa T, et al. Clinical importance of the LDL-C/apolipoprotein B ratio for neoimtational formation after everolimus-eluting stent implantations. J Atheroscler Thromb. 2021. https://doi.org/10.5551/jat.60954.
11. Tani S, Yagi T, Atsumi W, Kawauchi K, Matsuo R, Hayama A. Relation between low-density lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017;16(1):123.
12. Galal H, Samir A, Shehata M. Assessment of apolipoprotein B/apolipoprotein A-I ratio in non-ST segment elevation acute coronary syndrome patients: Egypt Heart J. 2020;72(1):27.
13. Boi A, Jamthikar AD, Saba L, Gupta D, Sharma A, Loi R, Laird JR, Khanna NN, Suri JS. A survey on coronary atherosclerotic plaque tissue characterization in intravascular optical coherence tomography. Curr Atheroscler Rep. 2018;20(7):33.
14. Niccoli G, Montone RA, Di Vito L, Gramegna M, Refaat H, Scalone G, Leone AM, Trani C, Burzotta F, Porto I, et al. Plaque rupture and intact fibrous cap assessed by optical coherence tomography portend different outcomes in patients with acute coronary syndrome. Eur Heart J. 2015;36(22):1377–84.
15. Jia H, Abhtahian F, Aguierre AD, Lee S, Chia S, Lowe H, Kato K, Yonetsu T, Vergallo R, Hu S, et al. In vivo diagnosis of plaque erosion and calcified nodule in patients with acute coronary syndrome by intravascular optical coherence tomography. J Am Coll Cardiol. 2013;62(19):1748–58.
16. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz AM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–75.
17. Falk E, Nakano M, Bentonz JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologist’s view. Eur Heart J. 2013;34(18):215–8.
18. Koo J, Hong DH, Kim JH, Cho JY, Joo HJ, Cho SA, Park JH, Hong SJ, Yu CW, Lim DS. Identification of plaque ruptures using a novel discriminative model populating biomarkers in patients with acute coronary syndrome. Sci Rep. 2020;10(1):20228.
19. Saia F, Komukai K, Capodanno D, Sirbu V, Musumeci G, Boccutti G, Tarantini G, Finesschi M, Tumminello G, Bernelli C, et al. Eroded versus ruptured plaques at the culprit site of STEMI: in vivo pathophysiological features and response to primary PCI. JACC Cardiovasc Imaging. 2015;8(5):666–75.
20. Yonetsu T, Lee T, Muri T, Suzuki M, Matsumura A, Hashimoto Y, Kakuta T. Plaque morphologies and the clinical prognosis of acute coronary syndrome caused by lesions with intact fibrous cap diagnosed by optical coherence tomography. Int J Cardioiol. 2016;203:766–74.
21. Iannaccone M, Quaini F, Gasser T, D’Ascenzo F, Montefusco A, Omede P, Jang IK, Niccoli G, Souteyrand Y, Yundt C, et al. Prevalence and predictors of culprit plaque rupture at OCT in patients with coronary
artery disease: a meta-analysis. Eur Heart J Cardiovasc Imaging. 2016;17(10):1128–37.
22. Sheng Z, Zhou P, Liu C, Li J, Chen R, Zhou J, Song L, Zhao H, Yan H. Relationships of coronary culprit-plaque characteristics with duration of diabetes mellitus in acute myocardial infarction: an intravascular optical coherence tomography study. Cardiovasc Diabetol. 2019;18(1):136.
23. Dai J, Fang C, Zhang S, Hou J, Xing L, Li L, Wang Y, Wang J, Yang Y, Tu Y, et al. Not all plaque erosions are equal: novel insights from 1,660 patients with STEMI—a clinical, angiographic, and intravascular OCT study. JACC Cardiovascular Imaging. 2020;13(2 Pt 1):516–8.
24. Dai J, Tian J, Hou J, Xing L, Liu S, Ma L, Yu H, Ren X, Dong N, Yu B. Association between cholesterol crystals and culprit lesion vulnerability in patients with acute coronary syndrome: an optical coherence tomography study. Atherosclerosis. 2016;247:111–7.
25. Nishimura S, Ebara S, Hasegawa T, Matsumoto K, Yoshikawa J, Shimada K. Cholesterol crystal as a new feature of coronary vulnerable plaques: an optical coherence tomography study. J Cardiol. 2017;69(1):253–9.
26. Kogo T, Hiro T, Nitani D, Takayama T, Fukamachi D, Monkawa T, Sudo M, Okumura Y. Macrophage accumulation within coronary arterial wall in diabetic patients with acute coronary syndrome: a study with in vivo intravascular imaging modalities. Cardiovasc Diabetol. 2020;19(1):135.
27. Cao M, Zhao L, Ren X, Wu T, Yang G, Du Z, Yu H, Dai J, Li L, Wang Y, et al. Pancoronary plaque characteristics in STEMI caused by culprit plaque erosion versus rupture: 3-vessel OCT study. JACC Cardiovascular Imaging. 2021;14(6):1235–45.
28. Dai J, Xing L, Jia H, Zhu Y, Zhang S, Hu S, Lin L, Ma A, Liu H, Xu M, et al. In vivo predictors of plaque erosion in patients with ST-segment elevation myocardial infarction: a clinical, angiographical, and intravascular optical coherence tomography study. Eur Heart J. 2018;39(22):2077–85.
29. Esper RJ, Nordaby RA. Cardiovascular events, diabetes and guidelines: the ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245–55.
30. Liu J, Wang S, Cui C, Cai H, Sun R, Pan W, Fang S, Yu B. The association between glucose-related variables and plaque morphology in patients with ST-segment elevated myocardial infarction. Cardiovasc Diabetol. 2020;19(1):109.
31. Funayama H, Yoshioka T, Ishikawa SE, Momomura S, Kario K. Close association of matrix metalloproteinase-9 levels with the presence of thin-cap fibroatheroma in acute coronary syndrome patients: assessment by optical coherence tomography and intravascular ultrasonography. Cardiovasc Revasc Med. 2020. https://doi.org/10.1016/j.carrev.2020.12.033.
32. Olejarz W, Lacheta D, Kubiak-Tomaszewska G. Matrix metalloproteinases as biomarkers of atherosclerotic plaque instability. Int J Mol Sci. 2020;21(11):3946.
33. Kobayashi N, Takano M, Hata N, Kume N, Shirakabe A, Okazaki Tsurumi M, Shirakabe A, Okazaki Nishimura S, Katoaka T, Shimada K, Yoshimaya M. Serum n-3 to n-6 polyunsaturated fatty acids ratio correlates with coronary plaque vulnerability: an optical coherence tomography study. Heart Vessels. 2014;29(5):596–602.
34. Zhao X, Wang Y, Chen R, Li J, Zhou J, Liu C, Zhou P, Sheng Z, Chen Y, Song L, et al. Triglyceride-glycolipid index combined with plaque characteristics as a novel biomarker for cardiovascular outcomes after percutaneous coronary intervention in ST-elevated myocardial infarction patients: an intravascular optical coherence tomography study. Cardiovasc Diabetol. 2021;20(1):131.
35. Grundy SM, Stone NJ, Bailey AL, Beam C, Birnher KK, Blumenthal RS, Braun LT, de Ferrari S, Faella-Tommasino J, Forman D, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHANASC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25):e1082–143.
36. Takarada S, Imanishi T, Kubo T, Tanimoto T, Kitabata H, Nakamura N, Tanaka A, Mizokushi M, Akasaka T. Effect of statin therapy on coronary fibrous-cap thickness in patients with acute coronary syndrome: assessment by optical coherence tomography study. Atherosclerosis. 2020;306:491–7.
37. Rached F, Santos RD. The role of statins in current guidelines. Curr Atheroscler Rep. 2020;22(9):50.
38. Munir A, Kim HO, Russo M, Araki M, Nakajima A, Lee H, Takano M, Mizuno K, Jiang IK. Relationship of low-density lipoprotein cholesterol level to plaque rupture. Am J Cardiol. 2020;134:48–54.
39. Yano H, Horinaka S, Ishimatsu T. Effect of evolocumab therapy on coronary fibrous-cap thickness assessed by optical coherence tomography in patients with acute coronary syndrome. J Cardiol. 2020;75(3):289–95.
40. Takakura S, Imanishi T, Ishibashi K, Komukai K, Ino Y, Kitabata H, Kubo T, Tanaka A, Kimura K, et al. The effect of lipid and inflammatory profiles on the morphological changes of lipid-rich plaques in patients with non-ST-segment elevated acute coronary syndrome: follow-up study by optical coherence tomography and intravascular ultrasound. JACC Cardiovasc Interv. 2020;13(7):766–72.
41. Gao Y, Lou Y, Liu Y, Wu S, Xi Z, Wang X, Zhou Y, Liu W. The relationship between residual cholesterol risk and plaque characteristics in patients with acute coronary syndrome: Insights from an optical coherence tomography study. Atherosclerosis. 2021;317:1–16.
42. Niccoli G, Cin D, Scalone G, Panbianco M, Abbolito S, Cosentino N, Jacoangeli F, Refaat H, Gallo G, Salerno G, et al. Lipoprotein(a) is related to coronary atherosclerotic burden and a vulnerable plaque phenotype in angiographically obstructive coronary artery disease. Atherosclerosis. 2016;246:214–20.
43. Szarek M, Bittner VA, Aylward P, Baccara-Dinet M, Bhatt DL, Diaz R, Fras Z, Goodman SG, Halvorsen S, Harrington RA, et al. Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering. ODYSSEY OUTCOMES trial. Eur Heart J. 2020;41(44):4245–55.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.